{"analyses":[{"ciLowerLimit":"3.19","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"17.77","estimateComment":"Odds ratio is for pomalidomide plus low-dose dexamethasone : high dose dexamethasone","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"< 0.001","paramType":"Odds Ratio (OR)","paramValue":"7.53","statisticalMethod":"Fisher Exact"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.5"},{"groupId":"OG001","value":"3.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"302"},{"groupId":"OG001","value":"153"}],"units":"Participants"}],"description":"Objective response is defined as a best overall response of stringent complete response (SCR), complete response (CR), very good partial response (VGPR) or partial response (PR) based on the Independent Response Adjudication Committee: SCR: CR and normal free light chain (FLC) ratio and no clonal cells in bone marrow; CR: Negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤ 5% plasma cells in bone marrow; VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥ 90% reduction in serum M-protein and urine M-protein level \\< 100 mg/24 hours; PR: ≥ 50% reduction of serum M-Protein and reduction in urinary M-protein by ≥ 90% or to \\< 200 mg/24 hours. In addition to the above, if present at baseline a ≥ 50% reduction in the size of soft tissue plasmacytomas is also required.","groups":[{"description":"Participants received 4 mg pomalidomide administered by mouth on Days 1-21 of each 28-day treatment cycle and 40 mg dexamethasone (participants \\> 75 years of age received 20 mg dexamethasone) administered by mouth once per day on Days 1, 8, 15, and 22 of a 28-day cycle until disease progression.","id":"OG000","title":"Pomalidomide Plus Low-Dose Dexamethasone"},{"description":"Participants received 40 mg dexamethasone (participants \\> 75 years of age received 20 mg dexamethasone) administered by mouth once per day on Days 1 through 4, 9 through 12, and 17 through 20 of a 28-day cycle until disease progression.","id":"OG001","title":"High-Dose Dexamethasone"}],"paramType":"NUMBER","populationDescription":"Intent-to-treat population","reportingStatus":"POSTED","timeFrame":"From randomization until the data cut-off date of 01 March 2013. Maximum time on follow-up was 93 weeks.","title":"Percentage of Participants With an Objective Response According to International Myeloma Working Group (IMWG) Uniform Response Criteria","type":"SECONDARY","unitOfMeasure":"percentage of participants"}